Skip to main content

Infants to Preschoolers IGA
Efficacy Results

In the treatment of infants to preschoolers (6 months to 5 years of age)
with uncontrolled moderate-to-severe atopic dermatitis

Clearer skin with
DUPIXENT + TCS

Visible results with DUPIXENT

In DUPIXENT clinical trials including infants to preschoolers, the primary endpoint was the proportion of subjects with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear) at Week 16.1

Actual patients in a Phase 3 DUPIXENT trial (AD-1539) in infants to preschoolers (aged 6 months to 5 years). Patients were prescribed concomitant low-potency TCS based on the clinical trial program. Patients 1, 2, and 3 were considered clinical responders. Individual results may vary.1,2

Patient 1: 4-year-old achieved a 2-point improvement in IGA

DRAG TO SEE
RESULTS

Patient 2: 4-year-old achieved a 3-point improvement in IGA

DRAG TO SEE
RESULTS

Patient 3: 3-year-old achieved a 2-point improvement in IGA

DRAG TO SEE
RESULTS

Patient 4: 2-year-old achieved a 2-point improvement in IGA

DRAG TO SEE
RESULTS

A clinical responder was defined as a patient achieving IGA 0 or 11

  • Patient 4 did not meet the primary endpoint in the clinical trial based on their IGA score at Week 16

Clearer skin IN AD-1539

6 MONTHS TO
5 YEARS OF
AGE
Skin clearance at Week 16 (primary endpoint)1,2,a,b

Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity
controlled and P value was nominal.

aFull Analysis Set includes all subjects randomized.1

bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1

EXPLORE MORE IGA
EFFICACY RESULTS

VIEW ADULT DATA VIEW ADOLESCENT
(12 TO 17 YEARS) DATA VIEW CHILD
(6 TO 11 YEARS) DATA

IGA assessed the overall severity of the clinical signs of atopic dermatitis2

A 0- to 4-point scoring system of the overall severity of atopic dermatitis skin lesions2

4

Severe
Disease

Severe erythema and severe
papulation/infiltration

3

Moderate
Disease

Moderate erythema and moderate
papulation/infiltration

2

Mild
Disease

Mild erythema and mild
papulation/infiltration

1

Almost
Clear

Just perceptible erythema, and
just perceptible papulation/infiltration

0

Clear
 

No inflammatory signs of atopic dermatitis
 

A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point improvement from baseline1

IGA, Investigator's Global Assessment.
Example representation of IGA scoring.
Not an actual patient.

Dosage and
administration

Thinking about prescribing DUPIXENT?
Find the information you need to get started.

Explore administration Options